Today: 2 March 2026
Subscribe
Browse Category

Mergers & Acquisitions 4 November 2025 - 8 November 2025

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer secured a deal to acquire obesity-drug developer Metsera for up to $10 billion after Novo Nordisk withdrew its rival bid, citing FTC antitrust concerns. Metsera shareholders are set to vote Nov. 13 on Pfizer’s offer of $65.60 in cash plus up to $20.65 per share in contingent value rights. Metsera’s board recommended approval. Metsera shares surged nearly 60% during the bidding.
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer will acquire Metsera for up to $10 billion after Metsera accepted a revised cash-and-CVR offer late Friday, ending Novo Nordisk’s competing bid. Metsera’s board cited U.S. antitrust risks with Novo’s proposal following FTC feedback. Pfizer will pay $65.60 per share plus a contingent value right of up to $20.65. A shareholder vote is set for Nov. 13, with closing expected soon after.
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer agreed to acquire Metsera for up to $10 billion, outbidding Novo Nordisk and ending a heated takeover battle. Metsera shareholders will vote on the deal Nov. 13, with closing expected soon after pending approvals. Shares of MTSR surged to $83.18 following the announcement. Regulators are expected to review the deal’s impact on the obesity-drug market.
8 November 2025
·····
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Comcast (CMCSA) Stock Today — Nov. 7, 2025: Sky–ITV Talks and a Potential WBD Bid Put M&A in Focus as Shares Hover Near $27

Comcast traded at $27.28 as of 2:33 p.m. ET after news that its Sky unit is in early talks to buy ITV’s U.K. TV business for about £1.6 billion. Reuters also reports Comcast is exploring a bid for Warner Bros. Discovery’s studio and streaming assets. Shares moved within a $27.02–$27.77 range on about 20.9 million shares. CMCSA closed at $27.31 yesterday and is down 27% year-to-date.
7 November 2025
···
Marvell Technology Stock Soars on AI Boom: Latest Price, Hot News & 2025 Outlook

Marvell Technology (MRVL) Slides as SoftBank Takeover Buzz Fades — Stock News for November 7, 2025

Marvell Technology shares fell 5% to $88.64 on Friday, reversing Thursday’s gains after reports that SoftBank explored a takeover earlier this year. The stock swung between $85.12 and $94.16 during the session. Investors are now focused on Marvell’s Q3 earnings set for December 2. Recent volatility has tracked shifts in AI and data-center demand.
7 November 2025
··
Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen (NYSE: SG) Cuts 2025 Outlook, Sells Spyce Robotics to Wonder for $186.4M After Weak Q3 — 11/7/2025

Sweetgreen’s Q3 FY2025 revenue fell 0.6% to $172.4 million, with same-store sales down 9.5% on weaker traffic. The company cut full-year guidance and agreed to sell its Spyce robotics unit to Wonder for $186.4 million, while licensing back the Infinite Kitchen tech. Spending from 25–35-year-olds dropped 15% in the quarter. Shares fell as much as 20% after hours.
7 November 2025
···
Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation (ACHR) Raises $650M, Moves to Buy Hawthorne Airport for $126M; Shares Slip After Q3 Update — Nov. 7, 2025

Archer Aviation announced a $650 million equity raise and a $126 million deal to assume the master ground lease at Hawthorne Airport near LAX, aiming to anchor its Los Angeles air-taxi network. The company reported a Q3 net loss of $129.9 million and said its Midnight eVTOL completed a 55-mile piloted flight. Archer’s stock traded near $8.88 mid-day. The Hawthorne deal remains subject to city approval.
7 November 2025
···
Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial agreed to be acquired by Aquarian Capital in an all-cash deal valuing the company at $4.1 billion, or $70 per share. The transaction, expected to close in 2026 pending approvals, would take Brighthouse private. Shares jumped about 26% premarket following the announcement. Brighthouse canceled its Q3 earnings call but reported $5.4 billion in total adjusted capital.
6 November 2025
··
Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive, Inc. priced an upsized offering of 2 million shares of its SATA preferred stock at $80 each, targeting $160 million in gross proceeds. The stock carries a 12% initial annual dividend and may fund Bitcoin purchases, among other uses. Semler Scientific filed an 8-K confirming Strive’s recent capital moves and Bitcoin holdings as their pending merger advances. Settlement is set for November 10, 2025.
6 November 2025
···
Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources shares rose 5.5% to $21.14 midday after reporting Q3 revenue of $449.9 million and adjusted EPS of $0.09, citing higher gas prices and lower costs. The company advanced a $430 million Shelby Trough asset sale, expected to close in December 2025. Three new Western Haynesville wells averaged initial production of 32 MMcf/d. Liquidity stood at $939.2 million as of September 30.
6 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
SNAP Stock Just Got a 48‑Hour Jolt: India Creator Boom, New Sticker Push—and a $14B TikTok Twist Investors Can’t Ignore

Snap (SNAP) earnings today — Nov. 5, 2025: Revenue up 10% to $1.51B; $400M Perplexity AI deal and $500M buyback lift sentiment

Snap reported Q3 2025 revenue of $1.507 billion, up 10% year over year, and a net loss of $104 million. Daily active users reached 477 million, up 8%. The company announced a $500 million share buyback and a $400 million AI partnership with Perplexity, set to roll out in 2026. Shares rose about 21% after hours.
5 November 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Google (GOOGL) Stock Today: Alphabet Rises on Apple–Siri AI Tie‑Up, Epic Play Store Settlement, and DOJ Nod for $32B Wiz Deal — Nov. 5, 2025

Alphabet shares rose about 2% intraday after reports that Apple will use Google’s Gemini AI to power a new Siri, and Google proposed a settlement with Epic Games to change Android app-store rules. Separately, Wiz’s CEO said the DOJ cleared Google’s $32 billion acquisition of the cloud-security firm. Alphabet and Apple did not comment. The Epic settlement awaits court approval.
5 November 2025
···
Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding shares jumped nearly 90% to $0.26 on Nov. 5 after the company said it received two preliminary buyout offers. Trading volume soared to 316 million shares, far above the three-month average. The China-based digital media firm, listed on Nasdaq, had a pre-spike market cap of about $1.5 million. CEO Bing Zhang leads the company, which rebranded as Cheer Holding in 2023.
5 November 2025
··
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

The SPDR S&P Regional Banking ETF (KRE) traded at $59.82, down 0.5% intraday, with $619.3 million in outflows last week. Q3 earnings from 94 regional banks missed revenue estimates by about 1.2% on average, but shares outperformed. Fifth Third announced a $10.9 billion all-stock deal for Comerica, targeting Q1 2026 close. Trepp reported CMBS office delinquencies at a record 11.76% in October.
5 November 2025
·········
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera shares jumped nearly 20% to $73.29 on November 4, 2025, hitting a 52-week high after Novo Nordisk raised its takeover offer to $86.20 per share, topping Pfizer’s $70 bid. Metsera’s board called Novo’s proposal “Superior.” A Delaware judge declined to halt the bidding war, fueling further gains. Pfizer has until midweek to counter Novo’s offer.
4 November 2025
···
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis shares closed at $86.24 on Nov. 4, up 5% after Q3 earnings beat estimates with $213.6 million revenue and $1.21 non-GAAP EPS. The stock is down about 20% over the past year but up 235% over five years. Axcelis announced an all-stock merger with Veeco Instruments in October, valuing the combined company at $4.4 billion. Wall Street rates the stock between Hold and Buy, with an average target of $97.
4 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma shares jumped about 135% to $10.77 on Nov. 4, 2025, after announcing a buyout by QOL Medical for $11 per share in cash. The $17 million deal, approved by both boards, is expected to close by year-end. Evoke’s only product is Gimoti, an FDA-approved nasal spray for diabetic gastroparesis. Q2 net sales rose 47% to $3.8 million, but the company remains unprofitable.
4 November 2025
··
1 … 14 15 16 17 18 … 20
Go toTop